Buy or Sell: CYTO Stock Forecast 2023, 2024, 2025, 2030 to 2050

Today, we’re going on a journey to explore the CYTO Stock Forecast for the years 2023 to 2050. Altamira Therapeutics, trading under the ticker symbol CYTO on the NASDAQ, is at the forefront of pioneering RNA therapeutics and delivery.

The company’s focus on addressing the challenges of RNA delivery has positioned it as a key player in the rapidly evolving field of genetic medicine. With a strong emphasis on RNA-based technologies, Altamira Therapeutics is poised to make a significant impact on the global healthcare landscape.

One of the key areas of focus for Altamira Therapeutics is the development of innovative RNA delivery systems. These systems are designed to silence gene expression, promote protein expression, and deliver RNA therapeutics to specific targets within the body.

About CYTO Company

NameAltamira Therapeutics
CEODr. Thomas Meyer
HeadquartersSt. Louis, Missouri, USA
ServicesRNA therapeutics and delivery
CountryUnited States
LocationsSt. Louis, Missouri
WebsiteAltamira Therapeutics
ProfileAltamira Therapeutics

Altamira Therapeutics is a biotechnology company that specializes in developing RNA-based therapeutics and delivery systems. The company’s proprietary RNA delivery platform, Altamira, comprises nanoparticles that can deliver RNA molecules, such as siRNA and mRNA, to specific targets within the body. Altamira Therapeutics’ focus on RNA delivery technology underscores the industry-wide recognition of this challenge.

In addition to its RNA delivery platform, Altamira Therapeutics is also developing two novel, early-stage drug candidates: AM-401 for KRAS-driven cancers and AM-411 for rheumatoid arthritis. The company’s extensive intellectual property portfolio, including compositions comprising peptide-polynucleotide complexes and proprietary manufacturing processes, underscores its commitment to innovation and long-term sustainability.

Keep an eye on CYTO’s share price today with real-time updates, and examine its performance on the stock market through comprehensive charts that display the fluctuations in CYTO’s stock price. we will also take into analyst recommendations at the end of the article.

CYTO Stock Price Live

Above, the chart presents historical prices for CYTO stock, illustrating its trending behavior. Below, the table provides detailed data on the stock’s open, high, low, and close prices, offering a comprehensive perspective for stock analysis.

CYTO Stock Price History

CYTO Stock Forecast 2023 to 2050

We will analyze the performance of the company’s shares in recent times and provide you with a well-researched CYTO Stock Forecast for 2023, 2025 to 2030, based on our Research knowledge and forecasting. let’s see first The fundamental analysis of CYTO Limited focuses on key factors to better understand the company’s valuation.


Diverse Revenue Sources: CYTO has multiple streams of revenue, which can be a sign of a diverse business model.

Research & Development Investments: High investment in R&D (18,375 TTM) suggests a focus on innovation and future growth.

Asset Base: With total assets of 6,303 (as of 12/30/2022), the company has a significant asset base.


Consistent Net Losses: CYTO has reported consistent net losses over the years, with -23,711 in the TTM, which is a significant concern for financial stability.

High Operating Expenses: Operating expenses (21,960 TTM) are high relative to revenue, indicating inefficiency or a high-cost structure.

Negative Working Capital: The negative working capital of -11,111 (as of 12/30/2022) indicates potential liquidity problems.

Declining Cash Position: A decreasing end cash position (-61.26 TTM) and negative free cash flow (-11,424 TTM) show financial distress.


Optimizing Cost Structure: There’s an opportunity to reduce costs, especially in general & administrative expenses and operating expenses, to improve profitability.

Capitalizing on R&D: The heavy investment in R&D could lead to breakthroughs or innovative products that could open new markets or revenue streams.

Asset Utilization: Better utilization of current assets and tangible assets could improve financial performance.


High Debt Levels: The total debt of 6,331 (as of 12/30/2022) coupled with consistent net losses could lead to financial solvency issues.

Market Competition: Continuous losses may affect the company’s competitive position in the market.

Economic Conditions: Fluctuating market and economic conditions could further strain the company’s financials, especially given its current weak position.

CYTO’s financials reflect a company with substantial assets and a strong focus on R&D but struggling with high operating costs, consistent losses, and liquidity issues. While there are opportunities to leverage its asset base and R&D investments, the company faces significant threats from its debt levels and challenging market conditions. The focus should be on cost optimization and capitalizing on R&D outcomes to steer towards profitability and sustainability.

CYTO Stock Forecast 2023

The year 2023 holds promise for Altamira Therapeutics as it is expected to witness significant milestones in the company’s RNA technology platform. With the potential divestiture/partnering of legacy assets, Altamira aims to unlock intrinsic value and secure non-dilutive funding, which could positively impact the stock price. Additionally, the filing of the first IND in 2024 and the out-licensing of the technology platform present opportunities for growth. Considering these factors, a conservative minimum target for CYTO stock by the end of 2023 could be $1.20, while a more optimistic maximum target could be $1.50.

CYTO Stock Forecast 2024

In 2024, Altamira is poised to make significant strides with the filing of its first IND and the potential commercialization of its showcase programs in oncology and rheumatoid arthritis. The successful progression of these programs and the validation of the RNA technology platform could drive investor confidence and positively impact the stock price. Therefore, a minimum target of $2.00 and a maximum target of $2.50 could be reasonable for CYTO by the end of 2024.

CYTO Stock Forecast 2025

By 2025, Altamira’s RNA technology is expected to come of age, with disruptive potential in human medicine and a rapidly growing number of RNA therapeutics. The company’s extensive proof of concept, successful testing in various disease models, and the unique RNA delivery technology platform could position CYTO as an attractive investment. With the potential commercialization of its programs and the out-licensing of the technology platform, CYTO’s stock price could see a minimum target of $3.50 and a maximum target of $4.50 by the end of 2025.

CYTO Stock Forecast 2030

Looking ahead to 2030, Altamira’s continued growth and potential expansion into new therapeutic areas could significantly impact the stock price. With a strong intellectual property portfolio, including coverage until 2034 and potential extensions, Altamira is well-positioned for long-term success. The company’s innovative RNA delivery technology and its ability to address major challenges in RNA delivery could drive sustained investor interest. Therefore, a minimum target of $8.00 and a maximum target of $10.00 could be feasible for CYTO by the end of 2030.

CYTO Stock Forecast 2035

By 2035, Altamira’s established position in the RNA therapeutics market and its continued advancements in therapeutic development could lead to further stock price appreciation. The company’s proprietary manufacturing process and worldwide exclusive license from Washington University provide a strong foundation for future growth. With the potential generation of further IP, Altamira’s stock price could see a minimum target of $15.00 and a maximum target of $18.00 by the end of 2035.

CYTO Stock Forecast 2040

In 2040, Altamira’s sustained success in the RNA therapeutics industry and its ability to capitalize on disruptive technology growth opportunities could drive continued stock price growth. The company’s unique RNA delivery technology platform and its focus on addressing previously undruggable pathways position CYTO for long-term value creation. Therefore, a minimum target of $25.00 and a maximum target of $30.00 could be within reach for CYTO by the end of 2040.

CYTO Stock Forecast 2050

Looking further ahead to 2050, Altamira’s continued innovation, strategic partnerships, and advancements in RNA therapeutics could solidify its position as a leader in the industry. The company’s ability to adapt to evolving market dynamics and its focus on disruptive technology could drive sustained stock price appreciation. With a long-term perspective, a minimum target of $40.00 and a maximum target of $50.00 could be plausible for CYTO by the end of 2050.

Long-Term CYTO Stock Forecast

YearMinimum TargetMaximum Target

Analyst Recommendations

Daily Low / High

Telegram Channel👉 Click Here 🎯
Facebook Page👉 Click Here 🎯

CYTO Stock Price in 2014?

– According to Google historical data, the price of CYTO on 15 AUG 2014 was 26,160 USD.

What is the Current CYTO Stock Price?

– As of 7 December 2023, the current stock price of CYTO is 0.56 USD Check out today’s current stock price.

CYTO Stock Forecast 2023?

– Based on our analysis, the maximum CYTO Stock Forecast in 2023 could be 1.50 USD.

To stay updated with the latest information related to the stock market and receive live stock market updates, follow Stockdhan and stay connected with us. Check out Today’s Share Market Open or Closed.

Google NewsFacebook

I would like to remind you that I am not authorized by the SEC to provide any financial advice or recommendations. As you know, Stock Forecast is not an exact science, That’s why I am conducting in-depth research and using different AI tools to predict share prices. My purpose is only educational, and I am using AI to see what the future of the stock might look like.

Disclaimer– These Stock Price Targets for “CYTO Stock Forecast” are only provided for informational purposes only. It does not constitute a recommendation to buy, sell, or hold CYTO stock. Investors should conduct their own research and analysis and consult with financial experts before making any investment decisions—


In 2015, I Started Working as a Blogger Now I am a Versatile Professional With Experience in Blogging and Content Writing. I entered the stock market as a beginner in 2017. I was passionate about the stock market and learned something new every day. I Conduct Thorough Research and Produce High-Quality Content for Our Readers. Every Piece of Content Is Based on My Extensive Expertise and In-Depth Research.